Form 4: Zevra Therapeutics Director Granted Stock Options

Corey Michael Watton, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Summary

• Corey Michael Watton, a Director at Zevra Therapeutics, Inc. (ZVRA), received a grant of 30,000 stock options on June 4, 2026.
• The stock options have an exercise price of $11.17 per share, which was the closing price on the grant date.
• These options were awarded as compensation for Mr. Watton's service on the company's board of directors.
• The options are subject to vesting conditions, with 100% vesting on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately prior to a change in control of the issuer, provided Mr. Watton is still serving on the board at the vesting date.
• The options have an expiration date of June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director and does not provide new financial performance data or strategic shifts.

Positives

• Director compensation in the form of stock options aligns the director's interests with shareholders.
• The grant of options indicates continued engagement and commitment from a board member.
• The exercise price being set at the closing price on the grant date is a standard and fair practice.

Negatives

• The filing does not contain any negative information.

Risks

• The value of the stock options is dependent on the future performance of Zevra Therapeutics' stock price.
• Vesting is contingent on continued service, meaning the director could forfeit unvested options if they resign or are removed.

Future Outlook

The future outlook for the stock options is tied to the company's stock performance and the director's continued service. The options will become valuable if the stock price increases above the exercise price of $11.17.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and align executive and board interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially encouraging decisions that benefit long-term stock value. However, it also represents potential future dilution if options are exercised.
• Employees: This filing does not directly impact employees.
• Creditors: This filing has no direct impact on creditors.
• Suppliers: This filing has no direct impact on suppliers.
• Customers: This filing has no direct impact on customers.

Next Steps

• Corey Michael Watton will continue to serve as a Director for Zevra Therapeutics, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• The company's stock performance will determine the value of the vested options.

Key Dates

Keywords

Zevra Therapeutics, ZVRA, Form 4, Stock Options, Director Compensation, SEC Filing, Beneficial Ownership, Equity Grant